Alicia Elmore, DO
Family Medicine · Cadillac, MINPI 1700887841
Payments from drug & device makers
Across 359 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$494
- GSK$474
- Boehringer Ingelheim$450
- Pfizer$325
- Novo Nordisk$318
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,008100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $1,046 |
| Lilly USA, LLC | 37 | $494 |
| GSK | 78 | $474 |
| Boehringer Ingelheim | 23 | $450 |
| Pfizer | 22 | $325 |
| Novo Nordisk | 22 | $318 |
| AstraZeneca | 12 | $245 |
| Amgen(2 entities) | 15 | $245 |
| Astellas Pharma US Inc | 11 | $171 |
| Otsuka America Pharmaceutical, Inc. | 8 | $157 |
| Merck | 5 | $111 |
| Exact Sciences | 5 | $85 |
| Radius Health, Inc. | 4 | $69 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Avanir Pharmaceuticals, Inc. | 4 | $63 |
| Sanofi Pasteur Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Novartis | 3 | $51 |
| Johnson & Johnson | 4 | $48 |
| Dexcom, Inc. | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Indivior Inc. | 1 | $32 |
| Bayer | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Verona Pharma, Inc. | 1 | $24 |
| Biogen | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Neurelis, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Abbott | 1 | $13 |
| Shield Therapeutics Inc | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
| Vertiflex, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$5,019 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyclarysOmaveloxolone | 12 | $375,337 |
| MounjaroTirzepatide | 93 | $113,526 |
| EliquisApixaban | 108 | $98,367 |
| OzempicSemaglutide | 56 | $96,881 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $96,119 |
| TrulicityDulaglutide | 80 | $91,714 |
| JardianceEmpagliflozin | 67 | $69,611 |
| FarxigaDapagliflozin Propanediol | 35 | $24,180 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $20,290 |
| MyrbetriqMirabegron | 27 | $19,930 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $11,687 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $8,827 |
| Omeprazole | 451 | $7,933 |
| OxycontinOxycodone Hcl | 12 | $7,063 |
| Levothyroxine Sodium | 564 | $6,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenSkyclarys | $23 | $375,33712 claims |
| Lilly USA, LLCMounjaro, Trulicity | $494 | $205,239173 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $474 | $107,806135 claims |
| PfizerEliquis, Premarin | $325 | $104,706121 claims |
| Novo NordiskOzempic | $318 | $96,88156 claims |
| Boehringer IngelheimJardiance | $450 | $69,61167 claims |
| AstraZenecaFarxiga | $245 | $24,18035 claims |
| Astellas Pharma US IncMyrbetriq | $171 | $19,93027 claims |
| AbbVieSynthroid | $1,046 | $2,07623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Cadillac
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.